| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ICECURE MEDICAL Aktie jetzt für 0€ handeln | |||||
| Di | ICCM says government policy has tightened the metals cycle | 1 | Miningmx | ||
| Mo | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mo | IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 | 77 | PR Newswire | Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rate
Incidence... ► Artikel lesen | |
| 09.02. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.02. | IceCure CFO Ronen Tsimerman to depart | 1 | Seeking Alpha | ||
| 09.02. | IceCure Medical: IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved | 323 | PR Newswire | Ronen Tsimerman will continue as CFO until successor is appointed
CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure"... ► Artikel lesen | |
| 12.01. | IceCure Medical: IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales | 150 | PR Newswire | Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution for the local... ► Artikel lesen | |
| 08.01. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 17.12.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.12.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.12.25 | IceCure Medical: IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes | 160 | PR Newswire | Cryogenic flow control enhances the efficacy and precision of cryoablation procedures
Robust IP portfolio becomes increasingly strategic as global interest in IceCure's... ► Artikel lesen | |
| 03.12.25 | IceCure Medical beruft außerordentliche Hauptversammlung für Januar 2026 ein | 2 | Investing.com Deutsch | ||
| 03.12.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.11.25 | IceCure Medical reports nine months ended results | 3 | Seeking Alpha | ||
| 19.11.25 | IceCure Medical: IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 | 267 | PR Newswire | Momentum building in the U.S. and rising interest globally following landmark FDA marketing authorization for local cryoablation treatment of low-risk breast... ► Artikel lesen | |
| 18.11.25 | What's Next: Icecure Medical's Earnings Preview | 1 | Benzinga.com | ||
| 18.11.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.11.25 | IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification | 572 | PR Newswire | CAESAREA, Israel, Nov. 14, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that... ► Artikel lesen | |
| 10.11.25 | IceCure Medical: IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction | 138 | PR Newswire | Mr. Levav's appointment ensures seamless and focused organizational structure as Company expands commercial activities in the U.S. following FDA marketing clearance for ProSense® CAESAREA... ► Artikel lesen | |
| 10.11.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 50,90 | -0,82 % | Dax-Konzern liefert: Fresenius legt starkes Jahresergebnis vor und erhöht die Dividende | © Foto: Arne Dedert/dpaEin starkes Schlussquartal treibt Fresenius zu soliden Jahreszahlen und höherer Dividende, doch die Aktie reagiert mit Verlusten.Der Gesundheitskonzern Fresenius hat im Geschäftsjahr... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 42,140 | -0,59 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Siemens Healthineers mit einem Kursziel von 55 Euro auf "Outperform" belassen. Die Nervosität der Anleger vor einem möglichen Verkauf des Diagnostikgeschäfts... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,220 | -5,83 % | Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics | Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,470 | +0,64 % | Gewinnwarnung von FMC, Oerlikon mit Sonderdividende und Takkt muss Dividende streichen - BÖRSE TO GO | Fresenius Medical Care überraschte am Morgen mit einer Gewinnwarnung. Trotz des starken Gewinnsprungs im Vorjahr sieht man schwarz für 2026. Oerlikon kündigte nach dem Barmag Verkauf eine Sonderdividende... ► Artikel lesen | |
| GERRESHEIMER | 16,950 | +7,96 % | Shortseller-Positionen aktuell: Auto1, FMC, Gerresheimer, Hensoldt, Nagarro, TeamViewer, Zalando | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 41,380 | +3,14 % | BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance | LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 27,120 | -0,59 % | Carl Zeiss Meditec AG: ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options | Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye care professionals a flexible way to collaborate - whether as a standalone cloud application or as an integrated... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 22,670 | -4,10 % | PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance | SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| OTTOBOCK | 57,00 | +1,97 % | Aktien KW 8. News. Knorr Bremse. Jost. Norma Group. Ottobock. HHLA. STEYR Motors. Deutsche Rohstoff. Hapag Lloyd. technotrans | Aktien: Beim DAX konnte man letztendlich die 25.000er Marke behaupten. Wäre eigentlich eine schöne Ausgangsbasis für weitere Kursavancen. Aber die Unsicherheit über die Entwicklung im Nahen Osten mit... ► Artikel lesen | |
| ECKERT & ZIEGLER | 15,420 | +1,65 % | EQS-AFR: Eckert & Ziegler SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Eckert & Ziegler SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Eckert & Ziegler SE: Vorabbekanntmachung... ► Artikel lesen | |
| PROGYNY | 17,685 | -20,55 % | Progyny, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| GENEDX | 79,77 | -1,87 % | These Analysts Slash Their Forecasts On GeneDx After Q4 Results | ||
| ESSILORLUXOTTICA | 225,00 | 0,00 % | Ray-Ban Meta: Preisfrage sorgt offenbar für Spannungen | ||
| ONEMEDNET | 1,030 | +53,27 % | OneMedNet-Aktie steigt nach Plattform-Launch um 90 % | ||
| PRIVIA HEALTH GROUP | 23,730 | -4,81 % | Privia Health Group, Inc.: Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results | All 2025 Operating and Financial Metrics At or Above High End of Guidance RangesFull-year 2025 Net Income +59.3% from 2024Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024Full-year... ► Artikel lesen |